Hyperparathyroidism and parathyroidectomy in X-linked hypophosphatemia patients

Beck-Nielsen, 2009, Incidence and prevalence of nutritional and hereditary rickets in southern Denmark, Eur. J. Endocrinol., 160, 491, 10.1530/EJE-08-0818 1995, Nat. Genet., 11, 130, 10.1038/ng1095-130 Liu, 2007, How fibroblast growth factor 23 works, J. Am. Soc. Nephrol., 18, 1637, 10.1681/ASN.2007010068 Alizadeh Naderi, 2010, Hereditary disorders of renal phosphate wasting, Nat Rev Nephrol, 6, 657, 10.1038/nrneph.2010.121 Carpenter, 2011, A clinician's guide to X-linked hypophosphatemia, J. Bone Miner. Res., 26, 1381, 10.1002/jbmr.340 Linglart, 2014, Therapeutic management of hypophosphatemic rickets from infancy to adulthood, Endocr Connect, 3, R13, 10.1530/EC-13-0103 Alon, 2003, Hypertension in hypophosphatemic rickets–role of secondary hyperparathyroidism, Pediatr. Nephrol., 18, 155, 10.1007/s00467-002-1044-6 Tournis, 2005, Co-existence of X-linked hypophosphatemic rickets (XLH) and primary hyperparathyroidism: case report and review of the literature, J. Musculoskelet. Neuronal Interact., 5, 150 Thomas, 1970, Parathyroid adenomas in chronic rickets, Am. J. Med., 49, 404, 10.1016/S0002-9343(70)80032-8 Rivkees, 1992, Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets, J. Clin. Endocrinol. Metab., 75, 1514 Tournis, 2011, Tertiary hyperparathyroidism in a patient with X-linked hypophosphatemic rickets, J. Musculoskelet. Neuronal Interact., 11, 266 Wu, 2000, Tertiary hyperparathyroidism in X-linked hypophosphatemic rickets, Intern. Med., 39, 468, 10.2169/internalmedicine.39.468 Firth, 1985, Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases, Am. J. Med., 78, 669, 10.1016/0002-9343(85)90411-5 Carpenter, 1994, Nocturnal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia, J. Clin. Endocrinol. Metab., 78, 1378 Knudtzon, 1995, Autonomous hyperparathyroidism in X-linked hypophosphataemia, Clin. Endocrinol., 42, 199, 10.1111/j.1365-2265.1995.tb01863.x Yavropoulou, 2010, Cinacalcet in hyperparathyroidism secondary to X-linked hypophosphatemic rickets: case report and brief literature review, Hormones (Athens), 9, 274, 10.14310/horm.2002.1277 Savio, 2004, Parathyroidectomy for tertiary hyperparathyroidism associated with X-linked dominant hypophosphatemic rickets, Arch. Surg., 139, 218, 10.1001/archsurg.139.2.218 Akinci, 2017, The effectiveness of cinacalcet as an adjunctive therapy for hereditary 1,25 dihydroxyvitamin D3-resistant rickets, J Clin Res Pediatr Endocrinol, 9, 172, 10.4274/jcrpe.3486 Alon, 2008, Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets, Clin. J. Am. Soc. Nephrol., 3, 658, 10.2215/CJN.04981107 Raeder, 2008, A case of X-linked hypophosphatemic rickets: complications and the therapeutic use of cinacalcet, Eur. J. Endocrinol., 159, S101, 10.1530/EJE-08-0383 Alon, 1984, Hyperparathyroidism in patients with X-linked dominant hypophosphatemic rickets–application of the calcium infusion test as an indicator for parathyroidectomy, Int J Pediatr Nephrol, 5, 39 Nakamura, 2017, Hypertension is a characteristic complication of X-linked hypophosphatemia, Endocr. J., 64, 283, 10.1507/endocrj.EJ16-0199 Blydt-Hansen, 1999, PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia, Pediatr. Nephrol., 13, 607, 10.1007/s004670050669 Schmitt, 2004, The enigma of hyperparathyroidism in hypophosphatemic rickets, Pediatr. Nephrol., 19, 473, 10.1007/s00467-004-1443-y Makitie, 2003, Prolonged high-dose phosphate treatment: a risk factor for tertiary hyperparathyroidism in X-linked hypophosphatemic rickets, Clin. Endocrinol., 58, 163, 10.1046/j.1365-2265.2003.01685.x Imel, 2010, Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations, J. Clin. Endocrinol. Metab., 95, 1846, 10.1210/jc.2009-1671 Carpenter, 2010, Circulating levels of soluble klotho and FGF23 in X-linked hypophosphatemia: circadian variance, effects of treatment, and relationship to parathyroid status, J. Clin. Endocrinol. Metab., 95, E352, 10.1210/jc.2010-0589 Larsson, 2004, Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis, Endocrinology, 145, 3087, 10.1210/en.2003-1768